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Patients with cardiovascular disease and diabetes are at potentially higher risk of
infection and fatality due to COVID-19. Given the social and economic costs associated
with disability due to these conditions, it is imperative that specific considerations for
clinical management of these patients be observed. Moreover, the reorganization of
health services around the pandemic response further exacerbates the growing crisis
around limited access, treatment compliance, acute medical needs, and mental health of
patients in this specific subgroup. Existing recommendations and guidelines emanating
from respective bodies have addressed some of the pressure points; however, there are
variations and limitations vis a vis patient with multiple comorbidities such as obesity. This
article will pull together a comprehensive assessment of the association of cardiovascular
disease, diabetes, obesity and COVID-19, its impact on the health systems and how
best health systems can respond to mitigate current challenges and future needs. We
anticipate that in the context of this pandemic, the cardiovascular disease and diabetes
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patients need a targeted strategy to ensure the harm to this group does not translate to
huge costs to society and to the economy. Finally, we propose a triage and management
protocol for patients with cardiovascular disease and diabetes in the COVID-19 settings
to minimize harm to patients, health systems and healthcare workers alike.
Keywords: coronavirus disease 2019 (COVID-19), healthcare services, cardiovascular diseases (CVDs), diabetes,
obesity, personal protective equipment (PPE), clinical algorithm
INTRODUCTION
On March 11th, 2020, coronavirus disease 2019 (COVID-19)
was designated as a global pandemic by the World Health
Organization (WHO). As of 28thMay, 5,716,271 confirmed cases
have been reported with ∼356,124 deaths globally from 188
countries (1). In a matter of months, this has escalated into an
unprecedented public health as well as an economic crisis. Several
studies have confirmed that patients with COVID-19 show
distinctive and relatively significant comorbidities of diabetes,
obesity and cardiovascular disease (CVD) (2–12). Furthermore,
COVID-19 patients with diabetes, obesity and CVD conditions
are at a higher risk of morbidity and mortality (6, 7, 13).
Conversely, patients with diabetes, CVD and obesity are also at a
higher risk of contracting COVID-19 infection (6, 7, 14). Broadly
speaking, CVD, diabetes and obesity are associated with poor
clinical outcomes (15, 16). Therefore, in the milieu of COVID-
19; public health systems, carers, and healthcare providers must
take appropriate measures to mitigate the infection risks in
this population and consider health system reorganization and
adoption of technologies to sustain ongoing management (17–
19). The frontline healthcare workers triaging and managing
COVID-19 patients should consider various risks and their
compounding effects on the prognoses of patients with CVD,
diabetes and/or obesity.
RISKS AND OUTCOMES OF COVID-19 IN
THIS POPULATION
Independent of other medical problems such as CVD, patients
with diabetes are at elevated risk for infection from COVID-
19 by 2-to-3 fold (13). This may be attributed to the reduced
functioning of the immune system caused by high blood glucose
levels (13). Moreover, diabetes is often accompanied by CVD,
obesity and old age, all of which are known to increase the risk of
infection (14). Outcomes of infection by COVID-19 are also poor
in this population. Of 72,314 patients from the Chinese Center
for Disease Control and Prevention case series, case fatality rate
(CFR) was elevated among those with diabetes and CVD; 7.3
and 10.5% respectively compared to an overall CFR of 2.3% (5).
Outcomes are worse in people with poorly controlled diabetes,
and in those with additional chronic medical conditions such as
CVD and obesity (7, 13).
A recent meta-analysis of eight studies from China including
46,248 infected patients showed themost prevalent comorbidities
were high blood pressure (17 ± 7%, 95% CI 14–22%) and
diabetes (8 ± 6%, 95% CI 6–11%), followed by CVD (5 ±
4%, 95% CI 4–7%) (6). At this time, though the mechanism
of these associations remains unclear, the potential explanations
include CVD being more prevalent in those with advancing
age, a functionally impaired immune system, elevated levels of
angiotensin-converting enzyme 2 (ACE2), or a predisposition to
COVID-19 for those with CVD (6). There is significant overlap
in risk factors of CVD and venous thromboembolism (VTE);
with CVD risk factors such as older age, smoking, and adiposity
associated with high VTE risk (20). A recent Chinese study on
1026 COVID-19 patients reported that 40% (n = 407) at high
risk of venous thromboembolism; and the high-risk patients
who didn’t receive prophylactic therapy (11%) developed venous
thromboembolism (21).
As of 4th April 2020, the Intensive Care National Audit
and Research Centre (ICNARC) in the United Kingdom (UK)
received notification of 2,621 COVID-19 positive cases requiring
critical care (22). Analysis of this data suggest a significantly
greater number of COVID-19 positive cases, than “seasonal”
non-COVID viral pneumonia patients, were obese, with body
mass index (BMI)≥30 kg/m2 (38% compared to 31%, chi-square
28.2, p < 0.00001). The requirement for ventilatory support
was equal between the obese and non-obese patients (76 and
68% of cases respectively, p = 0.077). Obesity was associated
with higher mortality rates in critical care when compared
to normal or underweight COVID-19 positive patients (58%
compared to 45%, chi-square 8.3 p = 0.004). These data derive
from the ICNARC case mix programme database. The case mix
programme is the national clinical audit of patient outcomes
from adult critical care coordinated by the ICNARC. For more
information on the representativeness and quality of these data,
we encourage readers to contact ICNARC (22).
GAPS, CHALLENGES, AND CONCERNS
ABOUT THE MANAGEMENT OF CVD AND
DIABETES
In the setting of COVID-19, specialist cardiologists and
endocrinologists are confronted with a number of critical
issues on management and treatment of CVD. There has been
speculation regarding the risk associated with the use of ACE
inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in
patients with COVID-19 (23, 24). This is particularly relevant
to patients with diabetes and CVD, many of whom rely on such
pharmacotherapy for the treatment of retinopathy, nephropathy
and hypertension (14). Though the ACEi and ARB are commonly
used in the management of CVDs (hypertension, coronary
artery disease, congestive heart failure) and diabetes, there are
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conflicting data from studies (13, 15, 16) demonstrating an
increase or having minimal effect on ACE2 levels (25–29).
Poor glycaemic index is known to cause immune suppression
through impaired neutrophil degranulation, deficient
complement system and phagocytosis (30). The co-existence
of CVD and diabetes is a known risk factor for several serious
respiratory viral illnesses such as Influenza (31). With poor
glycaemic control being correlated with worse prognosis in
diabetic patients infected with COVID-19, glucose control is
key to the prevention of infection and minimizing the severity
of and morbidity caused by infection (32). However, the swift
transition of primary health care provision from in-person
to teleconsultations has led to many patients being unable to
access services for regular check-ups, presumably due to lack
of literacy and access to appropriate technology. Moreover,
an increasing number of physicians have reported a sudden
decrease in the incidence of myocardial infarction, stroke, and
other acute conditions (33, 34). Given that the prevalence of
these conditions would be invariably the same, if not elevated,
in these circumstances, this indicates a problematic decline in
the number of patients presenting to hospital with these critical
conditions. Likewise, there are increasing concerns related to
the postponement of elective cardiac and vascular surgeries.
With pressure building on the available beds, it is imminent
that only a select group of patients with clinical indication in
which surgery cannot be postponed will receive the therapy
(35). Furthermore, impact of postponement on those who will
eventually receive prolonged and delayed surgery vis a vis their
long-term morbidity is not known. In patients with diabetes,
CVD or obesity, physical exercise is critical to improving
patient outcomes (36). With the implementation of self-isolation
however, the ability and motivation to engage in physical exercise
are greatly diminished.
Healthcare workers responsible for the care of patients
with diabetes and cardiovascular disorders infected with
COVID-19 face threats to their own well-being, being at risk
of exposure to a high viral load (37). Time is critical in acute
myocardial or cerebral infarction. Given the reorganization
of healthcare services, additional pressure on frontline
services for COVID-19 cases, repurposing of other physicians
to meet the demand, additional resources limitations are
being realized across the spectrum in delivering time-critical
reperfusion therapy (34). It is more likely that reperfusion
services will also have time-constrained service hours, and
due to palpable risks from COVID-19 positive patients to
healthcare workers delivering reperfusion therapy, there
will be significant negative impact and delays in reperfusion
therapy. All patients with acute neuro/cardiovascular events,
including acute myocardial infarction (AMI) and acute
ischemic stroke (AIS) may be recommended to follow
the overarching COVID-19 protocol to screen for any
positive cases in order to minimize the risk to healthcare
workers (34).
Refugees, undocumented immigrants and members of
aboriginal communities also have limited provisions of
access and medical relief in pandemic situations, due to
structural factors and poor socioeconomic conditions that
put them at compounded risk due to cardiovascular and
diabetes comorbidities.
EXISTING RECOMMENDATIONS AND
GUIDELINES FOR DIABETIC PATIENTS
Professional societies such as the American Association
of Clinical Endocrinologists (38) and European society of
endocrinology (39) are in agreement on the need for people with
diabetes to prevent and prepare for the spread of COVID-19 by
taking the regular precautions such as staying home as much as
possible and washing hands regularly. The guidelines also advise
people to continue taking their medication in order to maintain
glucose control and to stock up on an additional 30-day supply
of medication and supplies for monitoring blood glucose levels
at home. However, there are no specific guidelines targeted at
individuals with multiple comorbidities, such as obesity and
CVD. As per the guidance given by the International Diabetes
Federation in the context of COVID-19 pandemic, people with
diabetes are among those high risk categories that can have
serious illness (just like the flu) if they get the virus and it is best
not to rush to the hospital, to avoid transmitting the virus to
others and to allow priority arrangements to be made by medical
personnel, if needed, instead of having to wait in line (40). The
International Society for Pediatric and Adolescent Diabetes
(ISPAD) has updated its guidelines recently on 19 March 2020
amidst the recent COVID-19 pandemic (41).
NHS clinical guidelines for the management of diabetic
patients in COVID-19 recommend expedition of treatment
and discharge of inpatients, and the use of virtual clinics and
teleconsultations in primary and secondary care settings (42).
However, guidelines fail to address the need for extra measures
to be taken for care of patients with poor access and literacy
with regards to technology. Moreover, elderly patients and those
with chronic disability living in nursing homes or aged care
facilities are at heightened risk of infection. These patients
often have a high prevalence of comorbid cardiovascular and
diabetes risk factors which makes them vulnerable during a
pandemic such as COVID-19. Increasing reports of acts of
microaggression, xenophobia and discrimination are surfacing
since the inception of this pandemic. This is particularly relevant
to specific populations such as south-Asians, who have high rates
of diabetes (43).
CURRENT APPROACHES TO THE
MANAGEMENT OF CARDIOVASCULAR
PATIENTS
Current approaches to the management of this population
aim to continue care of patients during COVID-19, while
minimizing the risk of transmission to both healthcare workers
and patients. The current protocol at academic medical centers
in China for Acute Myocardial Infarction involves compulsory
screening for fever and respiratory symptoms, and any patients
with STEMI that have suspected or confirmed infection are
treated with emergency intravenous thrombolysis, in the
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absence of contraindications (44). For cardiologists in the
operating theater, strict guidelines regarding hand hygiene and
personal protective equipment (PPE) are followed, and the
number of people in operating theater is minimized (44). The
American College of Cardiology urges the implementation of
telehealth in all cardiology clinics (45). Other societies including
European Society of Cardiology, British Cardiovascular
Society, Cardiac Society of Australian and New Zealand
(CSANZ), High Blood Pressure Research Council of Australia
(HBPRCA), Australian National Heart Foundation (NHF) and
Australian and New Zealand Society of Cardiac and Thoracic
Surgeons (ANZSCTS) also recommend use of telehealth
services (17–19).
With regard to the use of ACEi and ARBs, several societies
have highlighted that due to the limited nature of the evidence
on this matter, it is advisable that ongoing management with
such medication may continue in patients with diabetes and
hypertension, unless otherwise clinically contra-indicated as per
the case profile (46–48). Ongoing studies will bring clarity
on the use of ACEi and ARBs in COVID-19 patients with
diabetes and hypertension. A recent study reported a higher
prevalence of CVD and more than 7% of patients suffer
myocardial injury from the infection (22% of the critically ill)
(49). Though ACE2 serves as the main gateway for infection,
the role of ACEi or ARBs requires further investigation.
Myocardial injury is present in more than a quarter of critical
cases and presents in two patterns: acute myocardial injury
and dysfunction on presentation; and myocardial injury that
develops as the severity of illness intensifies (49–52). The
continuation of clinically indicated ACEi and ARB medications
is recommended based on the available evidence at this
time though there are a number of promising treatments
under investigation, but none with proven clinical efficacy
to date. COVID-19 is proved to pose a challenge for heart
transplantation, impacting donor selection, immunosuppression,
and post-transplant management (52).
TABLE 1 | Summary of recommendations regarding COVID-19 in patients with diabetes and/or cardiovascular disease.
S. No Stage of COVID-19
infection
Interventions/indications
1 Prevention of infection
and containing
pandemic
1. Wash your hands frequently with soap and water for 20 s or clean with alcohol-based hand rub
2. Maintain social distancing (2 meters or 6 feet)
3. Cough or sneeze into tissue or elbow
4. Avoid touching your face
5. Sanitize surfaces frequently
2 Symptomatic stage 1. If the patient is feeling unwell, he/she should stay at home
2. If the patient has fever, cough and/or difficulty breathing, seek medical attention and call in advance
3. Follow the directions of your local health authority
3 Controlling diabetes
during illness
General sick day diabetes management principles (modified from ISPAD guidelines):
1. More frequent blood glucose and ketone (blood or urine) monitoring
2. Aim for a blood glucose level between 4 and 10 mmol/L (70–180 mg/dL) and blood ketones below 0.6 mmol/L
when the child is ill
3. NEVER STOP INSULIN: If there is FEVER, insulin needs are usually higher
4. Monitor and maintain hydration with adequate salt and water balance
5. Treat underlying illness and symptoms (fever)
4. URGENT specialist
advice/referral to
emergency
1. Fever or vomiting persists and/or weight loss continues, suggesting worsening dehydration and potential
circulatory compromise
2. Fruity breath odor (acetone) persists or worsens / blood ketones remain elevated >1.5 mmol/L or urine ketones
remain large despite extra insulin and hydration
3. The patient is becoming exhausted, confused, hyperventilating (Kussmaul breathing), or has severe abdominal
pain
4. Identify COVID-19 patients who are at high-risk of venous thromboembolism (VTE), including those with
prolonged immobility, overlapping cardiovascular disease (CVD) risk factors (adiposity, age and smoking) or with
high estrogen levels (including those on exogenous hormone therapy). Consider initiating appropriate prophylaxis.
If at higher risk of bleeding due to anticoagulation, adjust anticoagulation dose and duration as well as use of
mechanical compression
5. Patients with bodymass index (BMI) of 30 kg/m2 or higher should be considered at high risk given the association
of these patients with significantly higher mortality after COVID-19 infection. These patients need closemonitoring
over teleconsultation *
6. Patients who are at increased risk of QTc interval prolongation, life-threatening cardiac arrhythmic events
and/or sudden cardiac death (e.g., COVID-19 positive patients with: (a) history of diabetes and/or CVD, and/or
(b) those on post-exposure prophylaxis or treatment of COVID-19 using “off-label” drugs such as
hydroxychloroquine, azithromycin and lopinavir/ritonavir)
Source:Prepared and adapted by the authors from the ISPAD guidelines.
ISPAD: International Society for Pediatric and Adolescent Diabetes.
*Based on the analysis of Intensive Care National Audit & Research Centre (ICNARC) United Kingdom data set (analyzed on April 4, 2020).
↑Recommendations of the CVD and diabetes subcommittee of the COVID-19 Pandemic Health System REsilience PROGRAM (REPROGRAM) consortium.
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RISK OF LIFE-THREATENING CARDIAC
ARRHYTHMIC EVENTS
Growing evidence suggests that COVID-19 is burdened by
a higher risk of life-threatening cardiac arrhythmic events,
especially in group of patients with diabetes and/or obesity, with
important implications for survival (53). These life-threatening
arrhythmias are also related to inflammation that can increase
the duration of ventricular repolarization (QTc interval) (54).
A particular attention to inflammation and arrhythmias is
important in these patients that are frequently affected by QTc
prolongation (55, 56). Therefore, key electrocardiogram (ECG)
parameters such as QTc interval should be monitored in this
subgroup of patients. Surveillance of QTc could potentially
reduce the number of drug-induced ventricular arrhythmias
and sudden cardiac deaths (57). This is particularly relevant
as “off-label” agents such as hydroxychloroquine, azithromycin
and lopinavir/ritonavir are being increasingly used in post-
exposure prophylaxis or treatment of COVID-19 patients (57,
58). These drugs are proven to increase the risk of QTc interval
prolongation, ventricular tachycardia (torsades de pointes) and
sudden cardiac death (58).
RECOMMENDATIONS AND DISCUSSIONS
Patients with diabetes with multiple comorbidities, such as
obesity and CVD, should take extra precaution for the
prevention of possible infection risk due to COVID-19. They
are recommended to be in virtual contact with their primary
health carers, and to maintain glycaemic control with diligence.
To ensure the maintenance of adequate glucose control in
such exceptional circumstances, it is recommended that primary
health care physicians take additional interest/responsibility to
reach out to patients who have not presented for regular check-
ups. The main recommendations for pediatric and adolescents
with diabetes and CVD are summarized (Table 1). Due to the
alarming decline in patients presenting with emergent conditions
to hospitals and outpatient clinics, without any indications of a
fall in prevalence of these conditions, we would request public
health professions to take extra measures in reaching out to
patients regarding the safety of coming to hospitals and the
medical need to do so and benefit of getting timely acute
reperfusion therapy in eligible patients. Given the aggravated
risks, we propose a novel triage and management protocol that
takes into account risks with CVD and diabetes (Figure 1).
Virtual delivery of group exercise classes could be organized
for patients with diabetes, CVD or obesity, who are currently
restricted by social isolation. Cross-department and peer-to-peer
inter-specialty professional collaboration and communication
are recommended to adapt existing pandemic preparedness
and response strategies to manage patients with neuro
cardiovascular emergencies. Special protection must be observed
during interventions that produce aerosol (cardiopulmonary
resuscitation). This may lower the risk of infection to healthcare
workers and patients. Cardiovascular experts may brace
themselves for deployments in different settings, for limited,
extended or repurposed causes. The mobility of staff between
COVID-19 treatment units and other patient facing consultation
should be limited to avoid opportunities for nosocomial
transmission. COVID-19 and patients with CVD, diabetes
or obesity impact each other in compounding and negative
dimensions. These patients are at increased risk of COVID-
19 related hospitalization, morbidity and death; and those
with COVID-19 also show propensity to increasing and
emergent acute cardiovascular events. It is important to identify
COVID-19 patients who are at high risk of VTE so that
appropriate prophylaxis treatment could be initiated (22, 59).
Anticoagulation should be considered for VTE prophylaxis.
Given the high risk of bleeding in COVID-19 patients with
high VTE risk, considerations should include adjustments in
anticoagulant dose and duration as well as use of mechanical
compressions (22).
Obesity is associated with severe COVID-19 (7–12, 22, 60).
Moreover, obesity or higher BMI is known to be associated with
a higher risk of CVD, diabetes and hypertension—which are
independent predictors of poor outcomes in COVID-19 (50, 60).
The analyses of ICNARC data suggest that BMI≥30 kg/m2
should be used as a prognostic indicator of mortality in critical
care settings due to COVID-19 (22). Another recent study found
a significant association of the prevalence of obesity (defined by
BMI≥30 kg/m2) with severe COVID-19 (7).We recommend that
clinicians should consider BMI≥30 while estimating risks and
stratifying patients for early and ongoing intervention. Center for
Disease Control and Prevention (CDC) in the United States also
list obesity, although with a relatively higher BMI cut-off of ≥40
kg/m2, as an independent risk factor, of severe illness in COVID-
19 (61). There are concerns this BMI cut-off (≥40 kg/m2) might
mislead or compromise the safety of obese people at lower BMIs
(60). The current consortium recommends BMI cut-off of 30
kg/m2 in identifying patients with adverse COVID-19 prognosis.
Surveillance of ECG parameters is recommended to potentially
reduce the risk of life-threatening arrhythmic events and sudden
cardiac death in COVID-19 positive patients especially those
with history of diabetes and/or obesity and/or those on post-
exposure prophylactic treatment (53–58).
In addition to clinical management, public health
interventions must be adhered to such as masks (preferably
N95), washing hands, social distancing. A New England Journal
of Medicine study showed efficacy of face masks in preventing
further transmission of Coronavirus from symptomatic
individuals (62). It is evident from the guidance currently
issued between World Health Organization (WHO), the CDC in
United States, the Canadian Standards Association and Canadian
Federal guidance (Canada), and the UK that differences exist
in advice for healthcare workers to use respirators as opposed
to surgical face masks (63–65). The UK initially advocated,
“COVID-19 is classified as an airborne high consequence
infectious disease in the UK”, and instructed “ensure that staff
who are assessing or caring for suspected COVID-19 cases
are familiar with an FFP3 respirator conforming to EN149 [a
protection level higher than N95], and that fit testing has been
undertaken before using this equipment” (65). The current UK
position aligns with WHO guidance although recommending
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FIGURE 1 | Proposed cardiovascular disease and diabetes risk-adjusted, stage-wise, tele and in-hospital triage and management protocol. (1) All patients seeking
outpatient or in-hospital appointment, except the emergency cases, must dial into the hospital for a triage over telephone for risk assessment of COVID-19 cases prior
to consultation. The triage will be carried out by the relevant department officer, and will comprise a brief screening for signs, symptoms, and risk factors of COVID-19.
Questions should address recent travel history, fever, cough, sore throat, shortness of breath, fatigue, aches and pains, headaches, runny or stuffy nose, diarrhea,
sneezing, and loss of smell. Patients should be screened for their body mass index (BMI) and those with BMI ≥ 30 should be closely monitored and strongly advised
to self-isolate and follow public health guidelines. Patients with BMI ≥ 30 are at significant risk of mortality after COVID-19 infection. (2) All patients, despite risk factors
and symptoms, should be asked to attend a compulsory teleconsultation in order to minimize harm to both the patient and consultant. During the consultation, further
assessment of COVID-19 symptoms can be made, and potential impact on underlying diabetes/cardiovascular disease should be assessed. (3a) Should there be a
self-reported acute emergency by the patient, or a need for immediate medical attention as per the clinical judgement of the physician, the patient should be asked to
(Continued)
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FIGURE 1 | present at the emergency department; (b) If immediate medical assessment is not required, management should be carried out via teleconsultation. (4) In
the emergency department, the relevant steward must carry out secondary screening for COVID-19 symptoms. After screening, patients should undergo diagnostic
testing for COVID-19. Drive-through testing facilities should be deployed for all patients, to minimize exposure to health systems, health workers and the community.
Further imaging should also be carried out on patients, with extra precautions being taken to ensure proper cleaning of equipment when imaging COVID-19 positive
patients. (5a) For patients who require surgery, the acute management plan should be invoked. If the patient is COVID-19 positive, measures must be taken to protect
healthcare workers involved. Minimal number of staff should be involved at the direct interface and risk-minimization should be ensured for any peri-surgical
procedures that might involve aerosol production. For COVID-19 negative patients, the routine management plan should be followed; (b) If no surgery is required, the
non-acute management plan should be invoked. (6) A plan should be made to ensure proper quarantine of patients after discharge. This could include home isolation
and telemonitoring. Patients should be advised to follow hand hygiene, wear masks and practice social distancing.
risk assessment by the individual healthcare worker within the
guidance framework. The situation for Low- andMiddle-Income
Countries is made more difficult by a lack of resources and the
uncertain availability of respiratory and PPE often intended as
single use only.
Recently the CDC recommended wearing cloth face
coverings in public settings where other social distancing
measures are difficult to maintain (e.g., grocery stores and
pharmacies), especially in areas of significant community-
based transmission (66). Coronavirus like influenza and
rhinovirus can possibly spread through short range aerosol
transmission in exhaled breath. Therefore, this study
reinforces the need for individual and public health strategies
and the adoption of using face masks as a preventive
intervention. The American Academy of Ophthalmology
(AAO) recommends contact lens wearers to switch to
wearing glasses for a while to limit the risk of COVID-19
infection (67).
Pandemics like COVID-19, SARS and Spanish flu invoke
irrational and heightened fear which could be linked to
incidents of xenophobia and discrimination (68). A public
health crisis of this scale can quickly mutate into a social
and political crisis. Therefore, it is warranted that the political
and health systems leadership must continue transparent, open,
and respectful communication with all communities, with
special consideration for communities from marginalized and
vulnerable backgrounds, as they tend to have a disproportionately
poor cardiovascular and metabolic profile (68). Also, this
subgroup of patients often have relatively poor access to
health services and compromised provision of medical supplies,
which is exacerbated in a public health crisis situation, more
so for a sustained period as is the case with pandemics
such as COVID-19 with an estimated mortality of 3.4%
however the recent evidence suggests the rates are still
evolving (69, 70).
Patients with comorbid CVD, diabetes and obesity are
potentially vulnerable in a pandemic (68–70). It must be
considered that a significant number of healthcare workers
will have these same and other vulnerabilities due to pre-
existing health conditions, therefore institutional policies
should provide for redeployment away from COVID-19
patient direct contact or furlough. Some jurisdictions have
developed national policy or workplace sector guidance in
others there is likely a duty of care in law. Healthcare providers,
health systems and political leadership must account for the
heterogeneity, compounded infection and fatality risks, long-
term complications and special considerations for ongoing
management as well as the socio-economic factors that may
interfere with the health and well-being of patients with CVD,
diabetes and/or obesity. Technological innovation such as
telemedicine along with public health strategies may mitigate
some of these risks.
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